MEREO BIOPHARMA GROUP PLC Foreign Currency Transaction Gain (Loss), before Tax
MEREO BIOPHARMA GROUP PLC (MREO) reported Foreign Currency Transaction Gain (Loss), before Tax of $1.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$361.00K.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $1.63M.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$126.00K, a 101.80% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $1.87M.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for fiscal 2025 was -$6.34M, a 624.30% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for fiscal 2024 was $1.21M.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for fiscal 2023 was -$2.35M, a 186.19% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC foreign currency transaction gain (loss), before tax for fiscal 2022 was $2.72M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.27M 10-Q · filed 2026-08-11 | $1.14M derived: sum of 3 quarters · filed 2026-08-11 | $3.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.63M 10-Q · filed 2026-05-12 | $1.50M derived: sum of 2 quarters · filed 2026-05-12 | $3.38M derived: sum of 3 quarters · filed 2026-05-12 | -$1.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.75M derived: sum of 2 quarters · filed 2026-03-19 | -$3.58M derived: sum of 3 quarters · filed 2026-08-11 | -$6.34M 10-K · filed 2026-03-19 |
| 2025-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$3.45M derived: sum of 2 quarters · filed 2026-08-11 | -$6.22M 10-Q · filed 2025-11-10 | $772.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.09M 10-Q · filed 2026-08-11 | -$1.10M derived: sum of 3 quarters · filed 2026-08-11 | -$7.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$2.77M 10-Q · filed 2026-05-12 | $4.22M derived: sum of 2 quarters · filed 2026-05-12 | -$2.20M derived: sum of 3 quarters · filed 2026-05-12 | -$2.17M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $566.00K derived: sum of 2 quarters · filed 2026-03-19 | $597.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.21M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$6.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$6.39M derived: sum of 2 quarters · filed 2025-11-10 | -$5.78M 10-Q · filed 2025-11-10 | -$8.58M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $644.00K 10-Q · filed 2025-08-12 | -$2.16M derived: sum of 3 quarters · filed 2025-08-12 | $307.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $613.00K 10-Q · filed 2025-05-13 | -$2.19M derived: sum of 2 quarters · filed 2025-05-13 | $276.00K derived: sum of 3 quarters · filed 2025-05-13 | -$527.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$337.00K derived: sum of 2 quarters · filed 2025-03-26 | -$1.14M derived: sum of 3 quarters · filed 2025-03-26 | -$2.35M 10-K · filed 2025-03-26 |
| 2023-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.66M derived: sum of 2 quarters · filed 2024-11-12 | $455.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$803.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$2.01M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$1.21M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $2.72M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |